Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

SUMATRIPTAN; NAPROXEN SODIUM

SUMATRIPTAN; NAPROXEN SODIUM

Standard Dose
85MG; 500MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: None (Tentative Approval)
Summary

Approval overview SUMATRIPTAN; NAPROXEN SODIUM is listed in Drugs@FDA under application 090930 (ANDA).

Marketing status: None (Tentative Approval) Active ingredient SUMATRIPTAN; NAPROXEN SODIUM Form and strength TABLET; ORAL - 85MG; 500MG Sponsor DR REDDYS LABS LTD Submission history Latest submission status date: 2011-01-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview SUMATRIPTAN; NAPROXEN SODIUM is listed in Drugs@FDA under application 090930 (ANDA). Marketing status: None (Tentative Approval) Active ingredient SUMATRIPTAN; NAPROXEN SODIUM Form and strength TABLET; ORAL - 85MG; 500MG Sponsor DR REDDYS LABS LTD Submission history Latest submission status date: 2011-01-20 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)

Interaction Notes

  • No interaction notes stored yet.